BI 695502

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Carcinoma, Non-Small-Cell LungColorectal NeoplasmsHealthy

Phase 1

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

CompletedNCT01608087

Boehringer IngelheimHealthy

Start: 2012-05-01End: 2012-11-01Updated: 2019-11-08

Phase 3

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

CompletedNCT02272413

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2015-07-08End: 2018-11-16Updated: 2020-01-13

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

CompletedNCT02776683

Boehringer IngelheimColorectal Neoplasms

Start: 2016-06-08End: 2018-10-03Updated: 2019-11-21

Related Papers

Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

Colorectal Cancer2022-11-091 citations

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Expert Opinion on Investigational Drugs2017-06-2729 citations